Find a Trial

Trial Results


19 protocol(s) meet the specified criteria
20170543OPEN TO ACCRUAL
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100).
BTCRC-LUN17-127OPEN TO ACCRUAL
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer
CTO-BTCRC-LUN18-153OPEN TO ACCRUAL
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
CTO-BTCRC-LUN19-396OPEN TO ACCRUAL
A phase II study of adjuvant treatment with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm), IIA, IIB, and select IIIA [T3N1-2, T4N0-2] resected non-small cell lung cancer (NSCLC) and the clearance of circulating tumor DNA (ctDNA)
CTO-IUSCC-0701OPEN TO ACCRUAL
Immunological Profile Changes In Patients with Advanced Non-Small Cell Lung Cancer Undergoing Treatment with Checkpoint Inhibitor Monotherapy
CTO-IUSCC-0722OPEN TO ACCRUAL
Circulating tumor DNA as a predictive biomarker to individualize therapy in patients with stage III non-small cell lung cancer
CTO-IUSCC-0723OPEN TO ACCRUAL
Evaluating the incidence and outcomes of patients with stage III non-small cell lung cancer (NSCLC) whose tumors harbor STK11 and/or Keap1 mutations treated with chemoradiation (CRT) followed by consolidation immunotherapy
CTO-IUSCC-0726OPEN TO ACCRUAL
Significance of STK11/LKB1 or Keap1 mutations in Stage III Non-Small Cell Lung Cancer
CTO-LUN18-335OPEN TO ACCRUAL
IUCRO-0031OPEN TO ACCRUAL
Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma
IUSCC-0567OPEN TO ACCRUAL
Circulating Tumor Cells (CTC) in Lung Cancer
IUSCC-0662OPEN TO ACCRUAL
A pilot study evaluating the feasibility and safety of a fasting-mimicking diet in patients receiving systemic treatment for metastatic non-small cell lung cancer
IUSCC-0670OPEN TO ACCRUAL
Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting as a Potential Teachable Moment for Actively Smoking Family Members
IUSCC-0709OPEN TO ACCRUAL
Evaluation of MRM-Profiling as a Small Molecule Biomarker-Enrichment Strategy in Oncological Clinical Trials
OTHN-IIR-IUSCC-0733OPEN TO ACCRUAL
Functional and Molecular Analysis of Muscle in Patients With and Without Head and Neck Cancer Cachexia
PULM-IIR-DRCOPEN TO ACCRUAL
Analysis of DRC in lung disease
RAON-IIR-IUSCC-0711OPEN TO ACCRUAL
Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients with Lung Tumors in Close Proximity to the Chest Wall
RAON-NRG-LU005OPEN TO ACCRUAL
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.
S1701OPEN TO ACCRUAL
A RANDOMIZED PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL WITH OR WITHOUT RAMUCIRUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, RECURRENT, OR METASTATIC THYMIC CARCINOMA